Skip to main content
GIPResearch.com · Patent and Technology Research

Pharmacosmos Holding A/S Received a Patent for an Iron Compound

Pharmacosmos Holding are specialists in iron therapy.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for Pharmacosmos Holding A/S Received a Patent for an Iron Compound
Research and original publication material

Pharmacosmos Holding A/S Received a Patent for an Iron Compound — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Pharmacosmos Holding are specialists in iron therapy. They develop, manufacture and market medicines for the treatment of iron deficiency anaemia in humans and animals. They are furthermore specialists in developing and producing advanced carbohydrates for pharmaceutical and technical uses. They have their headquarters in Holbæk, Denmark and affiliates in the US, UK, Ireland, Germany, Sweden and Norway. They have grown considerably over the years and are at present more than 245 people working with all aspects of a fully integrated pharmaceutical company. In India, the Pharmaceutical business of Pharmacosmos Holding A/S is focused on Treatment of fetal metal deficiency, pharmaceutical composition comprising an iron carbohydrate, iron carbohydrate complex, producing an iron-dextran compound. Pharmacosmos Holding A/S filed patent application numbered 8145/DELNP/2011 that is titled A STABLE IRON OLIGOSACCHARIDE COMPOUND. This patent application has been granted as Patent Number 291100.  The invention covers chemical compounds. The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9 % by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia. During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that the  Claim(s) 1-27, 29-34 are statutorily non-patentable under the provision of clause ([d) of Section 3 and the compound is “known substance”. As a response technical and scientific arguments were presented.  Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.  

Discuss a research question related to Pharmacosmos Holding A/S Received a Patent for

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2019-08-23. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights